CancerDrs

Lung Cancer clinical trials in Texas

124 actively recruiting lung cancer trials at 51 sites across Texas.

Data from ClinicalTrials.gov · last refreshed

Payments from drug makers to the doctors running these trials

For 3 of the trials on this page, the pharmaceutical company funding the trial also disclosed payments to the physicians leading it — public data from the federal CMS Open Payments database. Paying clinical-trial investigators for site work is expected and necessary for industry-funded trials; the scale and source are simply useful context when you're deciding whether to enroll. See the full lung cancer transparency page →

Phase 2, Phase 3 Recruiting Network

Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer

This screening and multi-sub-study randomized phase II/III trial will establish a method for genomic screening of similar large cancer populations followed by assigning and accruing simultaneously to a multi-sub-study hybrid Master Protoco…

Sponsor: SWOG Cancer Research Network
NCT ID: NCT03851445
Sites in Texas:
  • Hendrick Medical Center — Abilene, Texas
  • The Don and Sybil Harrington Cancer Center — Amarillo, Texas
  • Parkland Memorial Hospital — Dallas, Texas
  • UT Southwestern/Simmons Cancer Center-Dallas — Dallas, Texas
  • UT Southwestern/Simmons Cancer Center-Fort Worth — Fort Worth, Texas
View on ClinicalTrials.gov →
Phase 3 Recruiting NIH

Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer

This phase III trial compares the effect of bevacizumab and osimertinib combination vs. osimertinib alone for the treatment of non-small cell lung cancer that has spread outside of the lungs (stage IIIB-IV) and has a change (mutation) in a…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT04181060
Sites in Texas:
  • Houston Methodist San Jacinto Hospital — Baytown, Texas
  • Saint Joseph Regional Cancer Center — Bryan, Texas
  • Houston Methodist Cypress Hospital — Cypress, Texas
  • Parkland Memorial Hospital — Dallas, Texas
  • UT Southwestern Simmons Cancer Center - RedBird — Dallas, Texas
View on ClinicalTrials.gov →
Phase 3 Recruiting Academic/Other

Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to the Brain

This phase III trial compares the effectiveness of fractionated stereotactic radiosurgery (FSRS) to usual care stereotactic radiosurgery (SRS) in treating patients with cancer that has spread from where it first started to the brain. Radia…

Sponsor: NRG Oncology
NCT ID: NCT06500455
Sites in Texas:
  • MD Anderson in The Woodlands — Conroe, Texas
  • Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center — Houston, Texas
  • M D Anderson Cancer Center — Houston, Texas
  • Memorial Hermann Texas Medical Center — Houston, Texas
  • MD Anderson West Houston — Houston, Texas
View on ClinicalTrials.gov →
Phase 2, Phase 3 Recruiting Industry

Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7

The Phase 2 portion of this study evaluates the efficacy and safety of MRTX849 monotherapy and in combination with pembrolizumab in cohorts of patients with advanced NSCLC with KRAS G12C mutation and any PD-L1 TPS and who are candidates fo…

Sponsor: Mirati Therapeutics Inc.
NCT ID: NCT04613596
Sites in Texas:
  • Local Institution - 007-554B — Abilene, Texas
  • Local Institution - 007-554G — Amarillo, Texas
  • Local Institution - 007-879-A — Arlington, Texas
  • Local Institution - 007-879-B — Arlington, Texas
  • Local Institution - 007-892-B — Austin, Texas
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)

The purpose of this study is to understand if PF-08046054 alone works well compared to standard-of-care docetaxel alone in participants with non-small cell lung cancer (NSCLC) with PD-L1 expression greater than or equal to 1% and had cance…

Sponsor: Pfizer
NCT ID: NCT07144280
Sites in Texas:
  • Texas Oncology - West Texas — Abilene, Texas
  • Texas Oncology-Northeast Texas — Allen, Texas
  • Texas Oncology- Central South. — Austin, Texas
  • Texas Oncology Central South — Austin, Texas
  • Texas Oncology- Central South. — Austin, Texas
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)

The purpose of ARTEMIDE-Lung02 is to assess the efficacy and safety of rilvegostomig in combination with platinum-based chemotherapy for the first-line (1L) treatment of patients with metastatic squamous non-small cell lung cancer (mNSCLC)…

Sponsor: AstraZeneca
NCT ID: NCT06692738
Sites in Texas:
  • Research Site — Fort Worth, Texas
  • Research Site — Houston, Texas
  • Research Site — Kingwood, Texas
  • Research Site — Lubbock, Texas
  • Research Site — Round Rock, Texas
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002)

The goal of this study is to evaluate intismeran autogene plus pembrolizumab versus placebo plus pembrolizumab for the adjuvant treatment of margin negative, completely resected Stage II, IIIA, IIIB (with nodal involvement \[N2\]) non-smal…

Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06077760
Sites in Texas:
  • UT Southwestern Medical Center ( Site 0061) — Dallas, Texas
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations

The purpose of this study is to evaluate efficacy and safety of Dato-DXd in combination with rilvegostomig or rilvegostomig monotherapy compared with pembrolizumab monotherapy as a first line therapy in participants with locally advanced o…

Sponsor: AstraZeneca
NCT ID: NCT06357533
Sites in Texas:
  • Research Site — Fort Worth, Texas
  • Research Site — Houston, Texas
  • Research Site — Houston, Texas
  • Research Site — Houston, Texas
  • Research Site — Kingwood, Texas
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)

The goal of this study is to learn if people who receive intismeran autogene and pembrolizumab after surgery are cancer-free longer than people who receive placebo and pembrolizumab. Researchers want to know if giving intismeran autogene a…

Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06623422
Sites in Texas:
  • Texas Oncology - DFW ( Site 8103) — Dallas, Texas
  • UT Southwestern Medical Center ( Site 0190) — Dallas, Texas
  • Houston Methodist Cancer Center ( Site 0191) — Houston, Texas
  • MD Anderson Cancer Center ( Site 0150) — Houston, Texas
  • Memorial Hermann Cancer Center ( Site 0172) — Houston, Texas
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer

The purpose of this study is to evaluate the efficacy and safety of divarasib and pembrolizumab compared with pembrolizumab and pemetrexed and carboplatin or cisplatin, for the first-line treatment of adult participants with KRAS G12C-muta…

Sponsor: Hoffmann-La Roche
NCT ID: NCT06793215
Sites in Texas:
  • Renovatio Clinical - El Paso — El Paso, Texas
  • JPS Health Network — Fort Worth, Texas
  • The University of Texas MD Anderson Cancer Center — Houston, Texas
  • Community Clinical Trials — Kingwood, Texas
  • Texas Tech Health Science Center — Lubbock, Texas
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)

A study to evaluate Pumitamig versus Durvalumab following concurrent chemoradiation therapy in participants with unresectable stage III Non-small Cell Lung Cancer (NSCLC)

Sponsor: Bristol-Myers Squibb
NCT ID: NCT07361497
Sites in Texas:
  • Texas Oncology - Amarillo Cancer Center — Amarillo, Texas
  • Texas Oncology-Austin Central — Austin, Texas
  • Texas Oncology — Denton, Texas
  • Local Institution - 0811 — Fort Worth, Texas
  • Local Institution - 0596 — Houston, Texas
View on ClinicalTrials.gov →
Phase 2, Phase 3 Recruiting Industry

Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer

This is a Phase 2/3, multisite, randomized, open-label study in participants with first-line non-small cell lung cancer (NSCLC). This study includes two substudies (substudy A and substudy B) that will recruit participants according to his…

Sponsor: BioNTech SE
NCT ID: NCT06712316
Sites in Texas:
  • Millennium Research and Clinical Development, LLC — Houston, Texas
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer

The purpose of this study is to evaluate efficacy and safety of osimertinib (tablet) in combination with Dato-DXd (i.v. infusion) compared with osimertinib (tablet) monotherapyas a first-line therapy in participants with locally advanced o…

Sponsor: AstraZeneca
NCT ID: NCT06350097
Sites in Texas:
  • Research Site — Dallas, Texas
  • Research Site — Houston, Texas
  • Research Site — Houston, Texas
  • Research Site — Webster, Texas
  • Research Site — Woodway, Texas
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)

The purpose of this study is to evaluate the safety and efficacy of a novel RAS(ON) inhibitor compared to docetaxel.

Sponsor: Revolution Medicines, Inc.
NCT ID: NCT06881784
Sites in Texas:
  • Texas Oncology - South Austin — Austin, Texas
  • Texas Oncology Dallas — Dallas, Texas
  • MD Anderson Cancer Center — Houston, Texas
  • Texas Oncology - Gulf Coast — The Woodlands, Texas
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Long-term Extension Study of PCI-32765 (Ibrutinib)

The purpose of this study is to collect long-term safety and efficacy data for participants treated with ibrutinib and to provide ongoing access to ibrutinib for participants who are currently enrolled in ibrutinib studies that have been c…

Sponsor: Janssen Research & Development, LLC
NCT ID: NCT01804686
Sites in Texas:
  • MD Anderson Cancer Center - University of Texas — Houston, Texas
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer

This is a Phase III, multisite, randomized, double-blinded study to investigate pumitamig (BNT327) combined with chemotherapy (etoposide/carboplatin) compared to atezolizumab combined with chemotherapy (etoposide/carboplatin) for the treat…

Sponsor: BioNTech SE
NCT ID: NCT06712355
Sites in Texas:
  • The University of Texas MD Anderson Cancer Center — Houston, Texas
  • Millennium Research and Clinical Development, LLC — Houston, Texas
  • Texas Oncology Cancer Center — Sugar Land, Texas
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer (DLLEVATE)

The purpose of this study is to evaluate the efficacy and safety of ZL-1310 compared to Investigator's Choice Therapy in participants with relapsed Small Cell Lung Cancer.

Sponsor: Zai Lab (Shanghai) Co., Ltd.
NCT ID: NCT07218146
Sites in Texas:
  • Zai Lab Site 02025 — Austin, Texas
  • Zai Lab Site 02046 — Dallas, Texas
  • Zai Lab Site 02025 — Odessa, Texas
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)

Researchers are looking for a better way to treat people who have advanced non-small cell lung cancer (NSCLC) with specific genetic changes called human epidermal growth factor receptor 2 (HER2) mutations. Advanced NSCLC is a group of lung…

Sponsor: Bayer
NCT ID: NCT06452277
Sites in Texas:
  • University Hospital Simmons Cancer Center Lung/Head Neck Clinic — Dallas, Texas
  • The University of Texas MD Anderson Cancer Center - Texas Medical Center — Houston, Texas
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study to Compare the Efficacy and Safety of BMS-986489 (BMS-986012+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).

The Purpose of the Study is to Compare the Efficacy and Safety of BMS-986489 (Anti-fucosyl-GM1+ Nivolumab Fixed Dose Combination) in Combination with Carboplatin plus Etoposide to that of Atezolizumab with Carboplatin plus Etoposide as Fir…

Sponsor: Bristol-Myers Squibb
NCT ID: NCT06646276
Sites in Texas:
  • Texas Oncology - Central/South Texas — Austin, Texas
  • Texas Oncology - Northeast Texas — Tyler, Texas
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer

The goal of this clinical study is to learn more about the study drug sacituzumab govitecan (SG; Trodelvy®; GS-0132; IMMU 132), versus standard of care (SOC) in participants with previously treated extensive stage small cell lung cancer (E…

Sponsor: Gilead Sciences
NCT ID: NCT06801834
Sites in Texas:
  • Hendrick Health System — Abilene, Texas
  • MD Anderson Cancer Center — Houston, Texas
  • Texas Oncology - San Antonio — New Braunfels, Texas
  • The University of Texas Health Science Center at Tyler — Tyler, Texas
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]

This is a phase 3 study of pembrolizumab in combination with carboplatin/taxane (paclitaxel or nab-paclitaxel) followed by pembrolizumab with or without maintenance sacituzumab tirumotecan (sac-TMT; MK-2870) in first-line treatment of meta…

Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06422143
Sites in Texas:
  • Memorial Hermann Cancer Center ( Site 0015) — Houston, Texas
  • Oncology Consultants P.A. ( Site 0124) — Houston, Texas
  • Mays Cancer Center ( Site 0132) — San Antonio, Texas
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer

This clinical trial is designed to assess the efficacy and safety of trastuzumab deruxtecan (T-DXd; Enhertu®) in combination with pembrolizumab versus platinum-based chemotherapy in combination with pembrolizumab in participants with no pr…

Sponsor: Daiichi Sankyo
NCT ID: NCT06899126
Sites in Texas:
  • University of Texas M. D. Anderson Cancer Center — Houston, Texas
  • Lumi Research — Kingwood, Texas
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)

The primary objective of the study is to compare sacituzumab tirumotecan combined with pembrolizumab to pembrolizumab alone with respect to overall survival (OS). The primary hypothesis is that the combination of sacituzumab tirumotecan an…

Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06170788
Sites in Texas:
  • Oncology Consultants P.A. ( Site 0129) — Houston, Texas
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations

Global, Phase 3, randomized, multicenter, open-label study evaluating the efficacy and safety of firmonertinib at a dose level of 240 mg QD compared to investigator's choice of osimertinib (80 mg QD) or afatinib (40 mg QD) in participants …

Sponsor: ArriVent BioPharma, Inc.
NCT ID: NCT07185997
Sites in Texas:
  • Texas Oncology — Dallas, Texas
  • The University of Texas MD Anderson Cancer Center — Houston, Texas
View on ClinicalTrials.gov →

Showing 25 of 124 trials with sites in Texas. See all lung cancer trials →

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-05-25